Impact of Molecular Drug Susceptibility Testing on the Time to Multidrug-resistant Tuberculosis Treatment Initiation
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCISCIEScopus
- 저널 순위
- JCR Q2Scopus Q1
- 저널
- JOURNAL OF KOREAN MEDICAL SCIENCE35(35) · pp.1 · 2020
- 피인용
- Web of Science 12Scopus 14KCI 1
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2019 1.705
- ISSN
- 1011-8934
저자
- 전두수제1저자Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea
- Kang, HyungseokDepartment of Chest Medicine, Masan National Tuberculosis Hospital, Masan, Korea
- Kwon, Yong-SooDepartment of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea
- Yim, Jae-JoonDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
- Shim, Tae Sun교신저자Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
초록
Background: The purpose of this study was to evaluate the current status and trends in the coverage of molecular drug susceptibility testing (mDST), and the impact of mDST on the time to multidrug-resistant tuberculosis (MDR-TB) treatment initiation in Korea. Methods: We included confirmed rifampin-resistant (RR)/MDR-TB patients who submitted application forms for novel drug uses to the National TB Expert Review Committee from September 1, 2016 to November 30, 2019. We retrospectively reviewed their medical records. Results: Of the 621 MDR/RR-TB patients, mDST was performed in 442 (71.2%); Xpert MTB/RIF (Xpert) alone in 109 (17.6%), MTBDR plus line probe assay (LPA) alone in 199 (32.0%), and both Xpert and LPA in 134 (21.6%) patients. The coverage rate of mDST has gradually increased to 70% in 2015, 50.7% in 2016, 67.9% in 2017, 75.2% in 2018, and 79.4% in 2019 (P for trend < 0.001). Median time to MDR-TB treatment initiation was 35 days (interquartile range(25-75) 0-72), which has gradually decreased during the study period (P < 0.001). Independent predictors of shorter time to MDR-TB treatment initiation were retreatment case (adjusted hazard ratio [aHR], 1.30; 95% confidence interval [CI], 1.10-1.54), Xpert testing (aHR, 2.42; 95% CI, 2.03-2.88), and LPA testing (aHR, 1.83; 95% CI, 1.55-2.16). Transfer to another healthcare facility was inversely related to shorter time to treatment initiation (aHR, 0.74; 95% CI, 0.63-0.88). Conclusion: mDST coverage is gradually increasing and contributes to reducing the time to MDR-TB treatment initiation. Further efforts are needed to achieve universal access to mDST and to properly integrate mDST into routine clinical practice.
키워드
TuberculosisDrug ResistanceMultidrug-Resistant TuberculosisTime to TreatmentKorea
식별자
- Scopus EID
- 2-s2.0-85089777337
- WoS UID
- 000569333600001
- KCI
- ART002623528



로그인
연구물 목록으로